Objective To investigate the influence of Tanshinone ⅡA Sulfonate Sodium Injection on platelet activation function in patients with unstable angina ( UA ) pectoris of coronary atherosclerotic heart disease with blood stasis syndrome. Methods Totally 80 patients with unstable angina pectoris of coronary atherosclerotic heart disease patients with blood stasis syndrome admitted to our hospita from January 2013 to August 2016 were randomly divided into two groups by single blind randomized grouping method,40 cases in each group. The control group was treated with western medicine alone,on this basis,the observation group was added Tanshinone ⅡA Sul-fonate Sodium Injection. After 2 weeks of treatment,the clinical total effective rate,angina attack frequency and quality of life score, platelet membrane surface glycoprotein expression were compared between the two groups. Results The total effective rate in the obser-vation group was 95. 00%,which was significantly higher than 80. 00% in the control group (P < 0. 05). After treatment,the anginal attacks in the two groups were significantly decreased(P < 0. 05),and the observation group decreased more obviously(P < 0. 05). The life quality scores in the observation group was significantly higher than that in the control group(P < 0. 05). Compared with before treatment,the expression level of platelet membrane glycoprotein CD63 and PAC-1 were significantly increased in the two groups after treatment(P < 0. 05),the expression level of CD42b after treatment was significantly decreased(P < 0. 05),and the expression level of platelet membrane glycoprotein in the two groups had significant difference(P < 0. 05). Conclusion Tanshinone ⅡA Sulfonate Sodium Injection in the treatment of unstable angina pectoris of coronary atherosclerotic heart disease patients with blood stasis syndrome has significant clinical efficacy,it can relieve angina symptoms,improve quality of life,inhibit the activation of platelet function,and it is good for improving prognosis.%目的 探讨丹参酮ⅡA磺酸钠注射液对冠状动脉粥样硬化性心脏病(简称冠心病)不稳定型心绞痛血瘀证及血小板活化功能的影响.方法 选取2013年1月至2016年8月收治的冠心病不稳定性心绞痛血瘀证患者80例,采取单盲随机分组法分为两组,各40例,对照组患者实施单纯西药治疗,观察组患者在对照组基础上加用丹参酮ⅡA磺酸钠注射液治疗,治疗2周后,比较两组患者的临床总有效率、心绞痛发作次数、生活质量评分、血小板膜表面糖蛋白表达水平.结果 观察组的临床总有效率为95.00%,明显高于对照组的80.00%(P<0.05);治疗后,两组患者的心绞痛发作次数均明显减少(P<0.05),且观察组治疗后的心绞痛发作次数明显低于对照组(P<0.05);观察组的生活质量评分明显高于对照组(P<0.05);相比于治疗前,两组患者治疗后的血小板膜糖蛋白CD63、PAC-1表达水平均明显上调(P<0.05),CD42b表达水平明显下调(P<0.05),且治疗后两组患者的血小板膜糖蛋白表达水平相比,差异有统计学意义(P<0.05).结论 丹参酮ⅡA磺酸钠注射液治疗冠心病不稳定型心绞痛血瘀证临床疗效显著,可有效缓解心绞痛症状,抑制血小板活化功能,有利于改善患者的预后.
展开▼
